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ABSTRACT: The aim of the present study was to investigate the efficacy of infliximab for the
treatment of extrapulmonary sarcoidosis.
A prospective, randomised, double-blind, placebo-controlled trial was conducted, with
infliximab at 3 and 5 mg?kg-1 body weight administered over 24 weeks. Extrapulmonary organ
severity was determined by a novel severity tool (extrapulmonary physician organ severity tool;
ePOST) with an adjustment for the number of organs involved (ePOSTadj). In total, 138 patients
enrolled in the trial of infliximab versus placebo for the treatment of chronic corticosteroid-
dependent pulmonary sarcoidosis.
The baseline severity of extrapulmonary organ involvement, as measured by ePOST, was
similar across treatment groups. After 24 weeks of drug-therapy study, the change from baseline
to week 24 in ePOST was greater for the combined infliximab group compared with the placebo
group. After adjustment for the number of extrapulmonary organs involved, the improvement in
ePOSTadj observed in the combined infliximab group was also greater than that observed in
placebo-treated patients, after 24 weeks of therapy. The improvements in ePOST and ePOSTadj
were not maintained during a subsequent 24-week washout period.
Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary
sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool
described in the present study.
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S
arcoidosis is a multisystem granuloma-
tous disease of unknown cause. The
disease may remit spontaneously or with
treatment. Sarcoidosis is chronic, or progressive,
in ,25% of patients. Such patients require
long-term therapy to avoid progressive organ
dysfunction. Corticosteroids are currently recom-
mended as the drug of choice for sarcoidosis
[1, 2]. However, the cumulative toxicities of
corticosteroids make their long-term use proble-
matic. Efforts should be made to taper corticos-
teroids to the lowest effective dose [1].
Due to the side-effects associated with long-term
use of corticosteroids, there is interest in alter-
native therapies for sarcoidosis. Other than
corticosteroids, drugs that have been studied in
sarcoidosis have included methotrexate [3],
hydroxychloroquine [4], azathioprine [5] and
cyclophosphamide [6, 7].
Recently, the scientific literature has reported
efficacy of tumour necrosis factor (TNF)-a
antagonists for the treatment of pulmonary and
extrapulmonary sarcoidosis [8–14]. There is a
sound rationale for this therapy, because TNF-a
is released by macrophages in patients with
sarcoidosis [15], and TNF-a is thought to be
integrally involved in the development of the
granulomatous inflammation [16]. Furthermore,
sarcoidosis patients whose disease is refractory
to treatment with corticosteroids tend to have
high levels of TNF-a in bronchoalveolar lavage
fluid [17]. Since patients with extrapulmonary
sarcoidosis, such as those with chronic skin
conditions, upper respiratory tract and neurolo-
gical involvement, tend to be recalcitrant to
corticosteroid therapy [6, 18, 19], TNF-a antago-
nists may be especially useful in these patients.
Infliximab is a chimeric immunoglobulin G mono-
clonal antibody directed against TNF-a [20]. A
randomised, double-blind, placebo-controlled
trial was conducted to evaluate the efficacy of
infliximab for chronic corticosteroid-dependent
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pulmonary sarcoidosis [21]. The primary end-point of the study
was improvement in forced vital capacity (FVC) after 24 weeks
of treatment [21]. The effect of infliximab on extrapulmonary
sarcoidosis organ involvement was evaluated as a secondary
end-point in the present study. An extrapulmonary physician
organ severity tool (ePOST) was developed for the current
evaluation and the results of sarcoidosis extrapulmonary organ
involvement in the trial were reported.
METHODS
Eligibility
Eligible adult patients were required to have histologically
proven sarcoidosis, diagnosed o1 yr prior to screening, and
evidence of parenchymal disease (stage II or III) on chest
radiographs. Additional eligibility criteria included an FVC of
50–85% of the predicted value and a Medical Research Council
dyspnoea score of at least grade 1 [22]. Patients were required
to have been treated with o10 mg?day-1 of prednisone
equivalent or one or more immunosuppressants for o3 months
prior to screening. Doses of these medications were to have
remained stable for o1 month prior to study entry. During the
study, background medication regimen and doses were to
remain stable.
Patients were excluded from the study if they had a history or
current evidence of latent or active tuberculosis, chronic or
serious infections within 2 months of screening, malignancy,
or congestive heart failure. Previous administration of inflix-
imab or other TNF-a inhibitors within 3 months of screening
also excluded patients from participation.
Study design
The present study was a phase 2, multicentre, double-blind,
placebo-controlled study, in which patients were randomised
in a 1:1:1 ratio to receive intravenous infusions of either
placebo, infliximab at 3 mg?kg-1 body weight or infliximab
at 5 mg?kg-1 body weight, at weeks 0, 2, 6, 12, 18 and 24, and
were followed through to week 52. The design was selected in
order to simultaneously assess the efficacy of infliximab
(placebo versus the combination of the 3 mg?kg-1 and 5 mg?kg-1
groups) and determine whether there was a dose–response
relationship (placebo versus 3 mg?kg-1 versus 5 mg?kg-1
groups). Randomisation was carried out by an interactive
voice recognition system (IVRS). Subject allocation to treatment
groups was performed using an adaptive stratified design with
the following strata: 1) investigational site; and 2) the presence
or absence of disfiguring facial sarcoidosis skin lesions (lupus
pernio), as determined by the investigator. The IVRS assigned
randomised subjects to a specific treatment assignment that
was known only to the unblinded pharmacist at the study site.
Assignments were not carried out by block randomisation but
were adjusted by a computer program to maintain overall
balance, using the strata described previously. Enrolment was
performed by study investigators and coordinators. The first
subject gave consent for enrolment on September 30, 2003 and
the last subject visit was on September 30, 2005. Infliximab was
provided by Centocor, Inc. (Malvern, PA, USA) and infusions
were administered over at least a 2-h period.
In total, 138 patients from 34 centres, 20 in the USA and 14 in
Europe (details in the Acknowledgements section), were
randomised between September 30, 2003 and August 31,
2004. Institutional Review Boards/Ethics Committees at the 34
participating sites approved the study and patients provided
written informed consent before any protocol-specific pro-
cedures were performed.
Efficacy and safety evaluations
The primary end-point was the change from baseline in the
FVC % predicted, at week 24. The results of this primary end-
point have been previously described [21].
The efficacy of infliximab in the treatment of extrapulmonary
sarcoidosis was assessed as a secondary end-point in the
present study. The definition of involvement of sarcoidosis in
an extrapulmonary organ was based on a clinical decision of
the principal investigator at each clinical centre. The principal
investigators were all experienced in the clinical presentation
and management of sarcoidosis. Sarcoidosis organ assessment
was performed using an ePOST that was designed for the
purpose of the present study. The ePOST examined the state of
sarcoidosis extrapulmonary organ involvement in 17 extra-
pulmonary organs (table 1). At each visit, each of the 17 organs
was evaluated by the study investigator. Investigators were
instructed to use all clinical information available to them,
including laboratory analyses and assessments by subspecia-
lists, to assess each organ system. Each organ was scored on a
TABLE 1 Organs evaluated in the extrapulmonary
physician organ severity tool score
Skin
Peripheral lymph nodes
Eyes
Liver
Spleen
Central nervous system
Peripheral nervous system
Parotid/salivary glands
Bone marrow
Ear
Nose
Throat
Cardiac
Renal
Bone/joint
Muscle
Gastrointestinal
TABLE 2 Severity assessment of each organ
Score Description
0 Not affected
1 Slight
2 Mild
3 Moderate
4 Moderate to severe
5 Severe
6 Very severe
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scale from 0 (not affected) to 6 (very severely affected; table 2).
Therefore, the ePOST score could range from 0 (0617) to 102
(6617). Since the ePOST score was a summation of all
extrapulmonary organ involvement and was not weighted
for specific organ involvement, major changes in one organ
may have had their effect on the ePOST score diluted by the
number of organs affected. To adjust for this potential
confounding effect, an adjusted ePOST (ePOSTadj) score was
calculated, which equalled the ePOST score divided by the
number of extrapulmonary organs involved at any time during
the study. Although it was a secondary end-point, the scoring
system for each organ was established a priori. However, the
ePOST was constructed post hoc in order to examine whether
infliximab had an effect on extrapulmonary sarcoidosis.
In an attempt to determine whether the organs of the most
important clinical impact were affected to a greater or lesser
degree than the other organs, separate ePOST scores were
calculated for ‘‘major organs’’ (cardiac, central nervous system,
peripheral nervous system, liver, bone marrow, renal and eyes)
and ‘‘minor organs’’ (bone/joint, muscle, skin, spleen, nose,
peripheral lymph nodes). The remaining organs were not
included because of the small number of patients who had
involvement in those organs.
Safety assessments were performed throughout, until week 52.
All adverse events that occurred between visits were reported.
Infusion reactions were defined as any adverse event that
occurred during or within 1 h of completing the study agent
infusion.
Statistical analyses
For the primary end-point, the treatment effect was tested
using ANCOVA. The details of analysis and results have been
described previously [21] and are not included in the present
study.
As a post hoc analysis, the ePOST score, which was the sum of
the severity scores for all 17 extrapulmonary organs, was
summarised by visit using descriptive statistics. No formal
statistical comparison was made. As part of the descriptive
statistics, nominal p-values were produced based on an
ANCOVA model, similar to that for the primary end-point,
for change from baseline. Descriptive statistics and nominal
p-values were also produced for ePOSTadj.
Individual organ involvements were also evaluated in addition
to the aggregation (i.e. ePOST). Due to the potential skewing of
the data, a nonparametric test, Wilcoxon rank-sum test, was
used to perform between-treatment comparisons. Nominal
p-values are provided. Since the comparisons are for descriptive
purposes, no adjustment was made for multiple comparisons.
RESULTS
Baseline characteristics
The baseline characteristics of the enrolled patients are shown
in table 3. Patients had a mean¡SD (range) age of 47.0¡9.3
(45–50) yrs, had a slight (56.5%) male predominance, had a
history of sarcoidosis for 6.9¡6.2 yrs and had a baseline FVC
of 68.7¡9.7% pred, and approximately one-third (29.7%) were
black. Approximately two-thirds (92 out of 136; 67.6%) of
patients had extrapulmonary sarcoidosis involvement. Two
patients who were randomised did not receive any study drug
and, thus, an ePOST was not performed. Both of these patients
were randomised to the infliximab 3 mg?kg-1 group. The
baseline clinical characteristics were comparable between the
placebo and the combined infliximab groups.
Table 4 shows the proportions of study patients with extra-
pulmonary organ involvement at baseline. Figure 1 shows the
number of extrapulmonary organs involved with sarcoidosis at
baseline, according to treatment group. At baseline, the
treatment groups were similar with regard to number of
organs involved. As required by the study protocol, all patients
had at least one organ, the lungs, affected. However, ,25% (33
out of 136) of patients presented with two organs involved,
and it was quite common (53 out of 136;,40%) to have three to
six organs affected.
Changes in organ involvement
Changes in organ involvement from baseline to week 24, as
assessed by ePOST scores, are presented in table 5. The
infliximab groups had fewer organs involved with sarcoidosis
TABLE 3 Patient baseline characteristics
Placebo Combined infliximab Total
Subjects n 45 93 138
Age yrs 45.3¡9.4 47.8¡9.1 47.0¡9.3
Male 26 (57.8) 52 (55.9) 78 (56.5)
Race
Caucasian 29 (64.4) 64 (68.8) 93 (67.4)
Black 16 (35.6) 25 (26.9) 41 (29.7)
Asian 0 (0.0) 2 (2.2) 2 (1.4)
Other 0 (0.0) 2 (2.2) 2 (1.4)
Extrapulmonary involvement 30 (66.7) 62 (68.1)# 92 (67.6)
Time since sarcoidosis histologically proven yrs 7.0¡6.2 6.9¡6.2 6.9¡6.2"
FVC L 2.86¡0.77 2.82¡0.78 2.83¡0.78
FVC % pred 68.8¡11.1 68.6¡9.1 68.7¡9.7
Data are presented as mean¡SD or n (%), unless otherwise stated. FVC: forced vital capacity; % pred: % predicted. #: n591; ": n5137.
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at week 24 compared with baseline, in 38% (34 out of 89) of
patients compared with only 16% (seven out of 44) of those
receiving the placebo.
The mean ePOST values over time in the placebo and
combined infliximab groups are shown in figure 2. Although
the mean¡SEM ePOST value at baseline was slightly higher in
the placebo group than in the infliximab group (4.00¡0.81
versus 3.55¡0.43, respectively), the difference was within
variability. The mean¡SEM ePOST values at week 24 for the
combined infliximab and placebo groups were 2.09¡0.32 and
3.70¡0.85, respectively. The improvement in ePOST scores at
week 24 was higher in the combined infliximab groups, as well
as the individual infliximab dose groups, compared with the
placebo group (p,0.01 for all comparisons). The improvement
in mean ePOST score was not maintained after infliximab
treatment was discontinued.
After adjustment for the number of extrapulmonary organs
involved, the improvement in the ePOSTadj score observed in
the combined infliximab groups was also statistically signifi-
cantly greater than that observed in placebo-treated patients at
the week 18, 24, 30 and 44 evaluations (p,0.05; fig. 3).
Table 6 describes the response of individual organs to
infliximab compared with placebo. Due to the small sample
sizes, no meaningful conclusions could be identified. Four
organs were not reported in table 6 (throat, parotid/salivary
glands, ear and gastrointestinal) because fewer than five
subjects had involvement of these organs at both baseline
and week 24. However in these four organs, the infliximab
groups scored the same or better than the placebo group in
every case. There were no substantial differences in the
concomitant medications used for sarcoidosis treatment within
or between groups [21]. Therefore, a stratified analysis of
ePOST scores was not required.
Table 7 shows the change in ePOST in two subgroups of
organs, major and minor (defined previously in the Methods
section), between week 0 and week 24. Compared with the
placebo, infliximab improved the ePOST more in the major
organs than in the minor organs, but not to a significant degree
(for further details see online supplementary data).
Adverse events
The adverse events of the present study have been
reported previously [21]. The proportions of patients who
had adverse events were similar across the treatment
groups. Infusion reactions occurred with 2.3% of infu-
sions in both the placebo (six out of 258 infusions) and
combined infliximab (12 out of 529 infusions) groups.
TABLE 4 Frequency of organ involvement at baseline
Organ Patients affected
Lungs 136 (100)#
Peripheral lymph nodes 50 (37)
Skin 36 (26)
Bone/joint 27 (20)
Liver 19 (14)
Eyes 19 (14)
Muscle 18 (13)
Cardiac 12 (9)
Peripheral nervous system 11 (8)
Nose 11 (8)
Central nervous system 9 (7)
Spleen 8 (6)
Renal 8 (6)
Bone marrow 5 (4)
Throat 3 (2)
Parotid/salivary glands 3 (2)
Ear 1 (1)
Gastrointestinal 1 (1)
Data are presented as n (%). #: two patients were randomised but did not
receive study agent; thus, organ involvement was not assessed.
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FIGURE 1. Bar graph of distribution of number of extrapulmonary organs
involved, according to treatment group. h: placebo group; &: combined infliximab
groups.
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FIGURE 2. Mean extrapulmonary physician organ severity tool (ePOST)
scores, with SEM bars, at each assessment visit, according to treatment group.
#: placebo group; $: combined infliximab groups. #: p50.0247; ": p50.0019. If
not specified, p.0.05. Comparisons between groups are based upon change from
baseline values.
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There were no anaphylactic or delayed hypersensitivity
reactions reported during the study.
DISCUSSION
The present double-blind randomised study demonstrated that
infliximab therapy improved extrapulmonary sarcoidosis
compared with placebo, as assessed by a novel severity tool,
the ePOST. Similar findings were observed when an adjust-
ment was made for the number of extrapulmonary organs
involved (ePOSTadj). All patients in the study were required to
be receiving a stable dose of corticosteroid or another
immunosuppressant to control their pulmonary sarcoidosis.
Therefore, the results of the present trial suggest that
infliximab provides additional benefit for extrapulmonary
sarcoidosis beyond that achieved with standard sarcoidosis
treatment.
The total score of extrapulmonary sarcoidosis severity was
decreased by .40% in the infliximab groups compared with
placebo after 24 weeks of therapy. The difference between
groups was not maintained after cessation of therapy at week
24. This was primarily due to the worsening in the infliximab
3 mg?kg-1 group [21]. Although investigators were encouraged
to keep the dose of any concomitant medications as consistent
as possible throughout the study, some patients did undergo
modifications in their concomitant medication regimen. The
impact of this remains unclear. In addition, the ePOST score
also showed improvement in the infliximab groups compared
with the placebo group when adjusted for the number of
organs involved. Thus, the present authors believe that it was
appropriate to calculate the ePOSTadj score as well as the
ePOST score because, otherwise, small changes in a few organs
were amplified in a severity score if a patient had a number of
organs involved.
There are several potential limitations of this severity tool.
First, the definition of involvement of sarcoidosis in an
extrapulmonary organ was arbitrary, based on the clinical
decision of the principal investigator at each clinical centre.
However, the principal investigators in the present study were
all experienced in the clinical presentation and management of
sarcoidosis. Although data concerning the degree of certainty
of the diagnosis of extrapulmonary organ involvement was not
available, the diagnosis should be predominantly accurate, as
three of the five most frequently identified extrapulmonary
organs were the peripheral lymph nodes, skin and eyes
(table 4). Confirmation of involvement of these organs was
probably by biopsy, the presence of lupus pernio facial skin
lesions or by ophthalmological examination. These are very
secure methods of diagnosis of sarcoidosis organ involvement
in patients with biopsy-proven pulmonary sarcoidosis.
However, detection of extrapulmonary organ involvement
was not standardised. Therefore, changes in extrapulmonary
organ involvement found by sensitive techniques (e.g. positron
emission tomography scanning) may have escaped assessment
in many patients. Secondly, the present severity tool has not
been previously validated as reproducible or related to clinical
outcome. Thirdly, the ePOST score was a summation of all
extrapulmonary organ involvement and did not include
weighting for specific organ involvement. Thus, major changes
in one organ may have been diluted by the number of organs
affected. For this reason, the ePOSTadj score was also
calculated, in an attempt to adjust for this confounding effect.
Also, patients with more extensive involvement of certain
organ systems might have had more supplementary informa-
tion available, upon which the physician could base their
assessment. Additional measures to evaluate each organ
system (i.e. laboratory analyses) were not mandated by the
protocol and it is possible that some physicians may have had
such information available to them while others did not.
The tool also weighted each organ similarly, while certain
organs probably have a greater impact on clinical function and
quality of life than others. For example, peripheral lymph
nodes were the most common site of extrapulmonary
sarcoidosis and, therefore, carried the most weight in the
ePOST assessment system. It is very likely that other
extrapulmonary organs were much more important. The
subgroups of organs that have a potential major clinical
impact (‘‘major organs’’) and those that have a minor clinical
impact (‘‘minor organs’’) were, therefore, examined. Subgroup
analyses, such as these, must be viewed with extreme caution,
as the subgroups were formed arbitrarily and the sample sizes
were smaller than for the entire cohort. Both subgroups
demonstrated a reduction in ePOST between week 0 and
TABLE 5 Change in number of extrapulmonary organs
involved from baseline to week 24
Placebo Combined infliximab
Total subjects 44 89
Change in organ number
f -1 7 (16) 34 (38)
0 30 (68) 49 (55)
o1 7 (16) 6 (7)
Data are presented as n or n (%).
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FIGURE 3. Mean adjusted extrapulmonary physician organ severity tool
(ePOSTadj) scores, with SEM bars, at each assessment visit, according to treatment
group. ePOSTadj is the ePOST score divided by the number of extrapulmonary
organs involved at any time during the study. #: placebo group; $: combined
infliximab groups. *: p,0.05.
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week 24. However, the ePOST did not reach statistical
significance in either subgroup, most probably because of the
smaller sample sizes when compared with the entire cohort. In
addition, problems of reproducibility and subjectivity of the
tool would be likely to create statistical noise and make the tool
less reliable, which would tend to make the tool less likely to
show differences between the placebo and infliximab groups.
Nevertheless, statistical differences were noted between the
placebo and infliximab groups despite these potential short-
comings. Another limitation was that the primary pulmonary
study [21] and the present secondary extrapulmonary study
may have suffered from a selection bias. Investigators may
have opted to administer infliximab in an open-label fashion to
patients with severe or progressive disease, thereby biasing
enrolment in the present study towards subjects with milder
disease. Such a bias may have made it more difficult to detect
significant changes due to infliximab therapy, but this remains
conjectural.
It should be noted that the severity of extrapulmonary
sarcoidosis was a secondary end-point of the present study.
Patients enrolled in this study were required to have the lung
as the primary organ of sarcoidosis involvement and, although
patients with extrapulmonary sarcoidosis were encouraged to
participate, this was not an eligibility requirement. Thus, some
patients with extrapulmonary manifestations of sarcoidosis
had more organs involved than others. It is conceivable that
patients with severe extrapulmonary sarcoidosis would have
responded differently to infliximab. However, the fact that the
present study patients with relatively mild extrapulmonary
sarcoidosis demonstrated a response to infliximab suggests
that this therapy might be effective for more severe extra-
pulmonary disease.
Another potential limitation of the present study is that the
duration of therapy was only 24 weeks. There appears to be a
dose-dependent increase in the risk of serious infections and
malignancies with anti-TNF-a antibody therapy [23].
Therefore, the risk–benefit ratio of infliximab therapy for
extrapulmonary sarcoidosis may not have been completely
assessed in the present trial.
Other sarcoidosis instruments have been developed to assess
the disease. A sarcoidosis assessment instrument was devel-
oped as part of the National Heart, Lung, and Blood Institute
study ‘‘A Case–Control Etiologic Study of Sarcoidosis’’
(ACCESS) [24]. However, this instrument was not appropriate
TABLE 6 Mean change in sarcoidosis organ score for each organ
Organ Placebo# Combined infliximab" Wilcoxon
p-value
Mean¡SD (range) Baseline+ Week 24+ Mean¡SD (range) Baseline+ Week 24+
Bone/joint -0.1¡0.85 (-2–4) 8 8 -0.2¡0.57 (-3–1) 19 11 0.580
Bone marrow 0.0¡0.46 (-2–2) 3 3 0.0¡0.24 (-1–2) 2 3 0.524
Cardiac 0.0¡0.30 (0–2) 4 4 -0.1¡0.36 (-2–1) 8 4 0.111
Central nervous system 0.1¡0.78 (-1–4) 3 5 0.0¡0.15 (-1–0) 6 5 0.582
Eyes 0.0¡0.46 (-1–2) 7 9 -0.1¡0.61 (-3–2) 12 10 0.841
Liver 0.0¡0.30 (-1–1) 3 3 -0.2¡0.54 (-3–1) 15 8 0.096
Peripheral lymph nodes -0.4¡0.79 (-3–0) 19 14 -0.3¡0.75 (-3–2) 31 23 0.390
Muscle -0.1¡0.47 (-2–1) 7 6 -0.1¡0.44 (-2–1) 11 9 0.588
Nose 0.1¡0.59 (-2–3) 3 4 -0.1¡0.63 (-4–1) 7 6 0.236
Peripheral nervous system 0.0¡0.51 (-3–1) 4 4 -0.1¡0.38 (-2–1) 7 6 0.281
Renal 0.0¡0.15 (0–1) 1 2 0.0¡0.32 (-1–2) 7 5 0.293
Skin -0.1¡0.69 (-4–1) 8 8 -0.3¡0.90 (-5–2) 26 17 0.087
Spleen 0.0¡0.15 (0–1) 0 1 -0.1¡0.38 (-2–0) 8 5 0.061
#: n544; ": n589; +: number of patients with involvement of that organ, i.e. organ score o1.
TABLE 7 Change in extrapulmonary physician organ severity tool (ePOST) scores for minor and major organs between week 0
and week 24
Placebo# Combined infliximab" Wilcoxon
p-value
Baseline Week 24 Change Baseline Week 24 Change
ePOST minor 2.50¡3.91 1.91¡3.17 -0.59¡2.19 2.28¡2.96 1.29¡2.00 -0.99¡1.96 0.174
ePOST major 1.41¡2.73 1.52¡2.67 0.11¡1.24 1.12¡1.85 0.74¡1.34 -0.38¡1.13 0.178
Data are presented as mean¡SD, unless otherwise stated. ePOST minor: sum of the scores for bone/joint, peripheral lymph nodes, muscle, nose, skin and spleen;
ePOST major: sum of the scores for bone marrow, cardiac, central nervous system, peripheral nervous system, liver, renal and eyes. #: n544; ": n589.
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for the present study because it determines whether an organ
is involved with sarcoidosis but does not assess the severity of
organ involvement. Instead, the ACCESS instrument was used
as a guide to define specific organ involvement. In addition,
WASFI et al. [25] developed a sarcoidosis severity score that was
derived by sarcoidosis experts who subjectively graded the
severity of 100 vignettes of sarcoidosis cases. The vignettes
were ‘‘broken down’’ into the items of objective information
that they contained, and then a logistic regression analysis
extracted the objective components upon which the experts
scored disease severity. The resulting equation was then
‘‘validated’’ by three additional international sarcoidosis
experts, who graded the same vignettes. Although this score
developed by WASFI et al. [25] would have been of interest in
the present study, it was published after the initiation of the
present trial.
In conclusion, the results of the extrapulmonary physician
organ severity tool assessment performed during the present
randomised, double-blind, placebo-controlled study suggest
that infliximab may be beneficial in the treatment of
extrapulmonary sarcoidosis in patients already receiving
corticosteroids. Further study of infliximab and other tumour
necrosis factor-a antagonists is warranted in this group of
patients.
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